Copyright © Inderes 2011 - present. All rights reserved.

Bioretec

0.57 EUR

-16.13 %

1,701 following

BRETEC

First North Finland

Medical Equipment & Services

Health Care

-16.13 %
-33.64 %
-56.00 %
-66.55 %
-75.12 %
-74.04 %
-61.10 %
-
-79.69 %

Bioretec operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio includes, for example, implants for pediatric and adult orthopedics and other materials for bone and soft tissue injuries. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic region.

Read more
Market cap
17.61M EUR
Turnover
220.24K EUR
P/E (adj.) (25e)
-1.87
EV/EBIT (adj.) (25e)
-1.58
P/B (25e)
1.88
EV/S (25e)
3.48
Dividend yield-% (25e)
-
Coverage
Recommendation
Reduce
Target price
0.60 EUR
Updated
2025-12-16
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 2025-12-17

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Something positive for a change. Bioretec has been granted U.S. Food and Drug Administration (FDA) Breakthrough Device Designation status. Time will tell if that turns into money at some point. Bioretec Tiedotteet | Bioretec Bioretec on suomalainen, globaalisti toimiva lääkinnällisi...
12/14/2025, 5:14 PM
by makuasia
23
Financial Goals: In line with the strategy and the priorities for the 2026-2028 period, Bioretec’s new financial goals are: Achieve a turnover of over 10 million euros by the end of 2028 Maintain an average sales margin of over 70% throughout the strategy period A new three-year ...
yesterday
by Umpi
12
Investors have certainly had to wait, and are still waiting quite patiently, for this to break through. In my opinion, the product itself, its purpose, and the benefits it brings are quite a no-brainer deal from the consumer’s perspective. However, commercialization and sales haven...
12/8/2025, 11:19 AM
9
Here are Antti’s comments regarding this latest release. Bioretec announced on Sunday that the U.S. Food and Drug Administration (FDA) has granted its RemeOs-DrillPin Breakthrough Device Designation status. The news is a positive indication of the company’s technology potential and...
12/15/2025, 6:26 AM
by Sijoittaja-alokas
8
Antti has made a new company report on Bioretec, after these companies’ new “updates”. Bioretec updated its strategy and financial targets for 2026–28. The company cut its 2028 revenue target to EUR 10 million (previously EUR 65 million). The turnaround in earnings also moved further...
10 hours ago
by Sijoittaja-alokas
6
Bioretec’s products are very good, and there seems to be a continuous active approach to their development work. Marketing is understandably quite different from that of a weight loss drug or a cancer drug, which, if successful, are quickly absorbed into the market. On the other ...
yesterday
6
If revenue reaches 10 million in three years, then the company has succeeded in something, meaning the growth slope would have increased. 2025 is roughly flat, so if we reach that 10 million, it’s good. Of course, the old targets were on a completely different scale, but so was the...
yesterday
by Expaco_b
6
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.